OBJECTIVES: To perform a cost-minimization analysis and budget impact of glycopyrronium bromide monotherapy versus tiotropium bromide monotherapy as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) from the perspective of the mexican public healthcare system. METHODS: Using data from GLOW 5 study, it was established the equivalence of safety and efficacy of glycopyrronium bromide monotherapy and tiotropium bromide monotherapy, so it is evaluated the annual costs of each therapy to establish the cost-savings with glycopyrronium bromide monotherapy. COPD drug cost was estimated for one year in the cost-minimization analysis, using local prices for public healthcare institutions (IMSS). It was developed a 5 year horizon budget impact from the perspective of the mexican public healthcare system with an annual discount rate of 5%. The total population used for the budget impact was calculated according to the CONAPO’s mexican population projection with 40 years old or over, the prevalence of the COPD in Mexico (PLATINO study) and the proportion of people that uses biomass for cooking. A deterministic sensitivity analysis was performed in both cases.  RESULTS: Annual cost of glycopyrronium bromide monotherapy was US$265.27 and for tiotropium bromide monotherapy was US$242.30 in one year horizon with a percent difference of 10.16% per patient. The budget impact costs in the first year were $287,409,746.74 and $262,527,500.25 for tiotropium bromide monotherapy and glycopyrronium bromide monotherapy respectively, with savings of 9.5% using glycopyrronium bromide monotherapy. CONCLUSIONS: Glycopyrronium bromide monotherapy is less costly than tiotropium bromide monotherapy which shows us that is possible to achieve cost-savings with at least the same clinical benefit from the perspective of the Mexican public health system, in specific from IMSS. *IMSS (Mexican Institute of Social Security) *CONAPO (National Council of Population) *Exchage rate 14.55 MXN